Examine the institutional and regulatory challenges India faces in mainstreaming Ayurveda as a globally recognised healthcare system.

NITI Aayog's Strategic Roadmap for Making Ayurveda Global, released on 2 July 2026, records Ayurvedic exports rising from USD 1.09 billion (2014) to USD 2.16 billion (2023) across nearly 150 countries [1]. Yet the roadmap's own framework of availability, acceptability and propagation [2] shows that institutional thinness and regulatory non-recognition, not demand, are the binding constraints.

Institutional challenges

• Skewed workforce: of over 3.55 lakh trained practitioners, roughly 95% practise within India, leaving a thin professional base to deliver Ayurveda abroad [1].
• Evidence deficit: WHO's Global Traditional Medicine Strategy 2025–2034 identifies the lack of research methods suited to traditional medicine as a core obstacle to building acceptable clinical evidence [4].
• Fragmented ownership: the roadmap needed convergence of NITI Aayog, the Ministry of Ayush and the MEA [1] — reflecting the absence of a single institution accountable for global outreach.
• Education portability: the NCISM Act, 2020 standardises Indian System of Medicine education domestically [3], but Indian qualifications enjoy no automatic cross-border recognition.
• Underleveraged platforms: the WHO Global Centre for Traditional Medicine, Jamnagar — the world's first such centre [5] — is yet to convert into regulatory traction abroad.

Regulatory challenges

• Divergent national regimes: WHO notes that variations in regulatory approaches across countries directly affect safety and quality assurance [4]; Ayurvedic formulations are consequently classified inconsistently in importing markets.
• Quality compliance: harmonising manufacturing and pharmacopoeial standards is essential, since safety and regulation form a distinct WHO strategic objective [4].
• Market access: the roadmap itself prioritises expanding market access and strengthening regulatory frameworks for international recognition [1] [2].
• Knowledge protection: WHO flags misappropriation of traditional knowledge as an unresolved rights concern [4].

Ayurveda's globalisation therefore hinges less on promotion than on credible institutions and interoperable rules. Investing in trial-grade evidence, mutual recognition agreements for practitioners, and WHO-aligned quality standards can convert cultural goodwill into regulated market access — advancing both universal health coverage and the Viksit Bharat@2047 vision the roadmap serves [1].